CN108076628A - 药物组合物和缺氧相关疾病的治疗方法 - Google Patents

药物组合物和缺氧相关疾病的治疗方法 Download PDF

Info

Publication number
CN108076628A
CN108076628A CN201680049299.7A CN201680049299A CN108076628A CN 108076628 A CN108076628 A CN 108076628A CN 201680049299 A CN201680049299 A CN 201680049299A CN 108076628 A CN108076628 A CN 108076628A
Authority
CN
China
Prior art keywords
pharmaceutical composition
disease
tpen
compound
hypoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680049299.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·Y·阿佩尔鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN108076628A publication Critical patent/CN108076628A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680049299.7A 2015-08-24 2016-09-13 药物组合物和缺氧相关疾病的治疗方法 Pending CN108076628A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208914P 2015-08-24 2015-08-24
PCT/US2016/051482 WO2017035542A1 (en) 2015-08-24 2016-09-13 Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases

Publications (1)

Publication Number Publication Date
CN108076628A true CN108076628A (zh) 2018-05-25

Family

ID=58101120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680049299.7A Pending CN108076628A (zh) 2015-08-24 2016-09-13 药物组合物和缺氧相关疾病的治疗方法

Country Status (8)

Country Link
US (1) US10653685B2 (https=)
EP (1) EP3340985B1 (https=)
JP (1) JP6849683B2 (https=)
CN (1) CN108076628A (https=)
AU (1) AU2016311504A1 (https=)
CA (1) CA2996614C (https=)
IL (1) IL257689B (https=)
WO (1) WO2017035542A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246503A1 (en) * 2021-05-24 2022-12-01 The Florey Institute Of Neuroscience And Mental Health Methods for mediating vasoconstriction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082851A (en) * 1989-02-20 1992-01-21 Hadassah Medical Organization Pharmaceutical composition for protecting the heart comprising a heterocyclic ethylenediamine derivative and methods for the use thereof
WO2004084799A2 (en) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
CN1816359A (zh) * 2003-05-05 2006-08-09 宾-古里安尼格夫大学研究及发展部 可注射的交联聚合制剂及其应用
CN101677950A (zh) * 2007-03-13 2010-03-24 生物信息处方有限公司 促进肌肉组织修复的方法
US20120276152A1 (en) * 2011-04-29 2012-11-01 Syed Hossainy Systems and methods of using zinc-chelator to treat myocardial infarction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003445A1 (en) 2011-06-30 2013-01-03 Athena Cardionet Ltd. Tetra-pyridine compounds and composition for protecting cells, tissues and organs against ischemia-reperfusion injury

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082851A (en) * 1989-02-20 1992-01-21 Hadassah Medical Organization Pharmaceutical composition for protecting the heart comprising a heterocyclic ethylenediamine derivative and methods for the use thereof
WO2004084799A2 (en) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
CN1816359A (zh) * 2003-05-05 2006-08-09 宾-古里安尼格夫大学研究及发展部 可注射的交联聚合制剂及其应用
CN101677950A (zh) * 2007-03-13 2010-03-24 生物信息处方有限公司 促进肌肉组织修复的方法
US20120276152A1 (en) * 2011-04-29 2012-11-01 Syed Hossainy Systems and methods of using zinc-chelator to treat myocardial infarction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YELENA A. SHMIST ET AL.: "TPEN Improves Myocardial Protection against Ischemia by Modulation of Intracellular Ca2+ Homeostasis", 《JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *

Also Published As

Publication number Publication date
AU2016311504A1 (en) 2018-03-08
IL257689A (en) 2018-04-30
IL257689B (en) 2021-03-25
EP3340985A4 (en) 2019-04-10
US10653685B2 (en) 2020-05-19
CA2996614C (en) 2023-12-12
JP2018527407A (ja) 2018-09-20
WO2017035542A1 (en) 2017-03-02
JP6849683B2 (ja) 2021-03-24
CA2996614A1 (en) 2017-03-02
US20180243276A1 (en) 2018-08-30
EP3340985A1 (en) 2018-07-04
EP3340985B1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
CA2641815C (en) Method of treatment for muscular dystrophy
US12070458B2 (en) Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
US20150079193A1 (en) Compositions and methods for inducing angiogenesis
JP6666899B2 (ja) Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
KR20160102301A (ko) 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도
AU2016328156B2 (en) Use of trientine to deliver copper to ischemic tissue
US11040020B2 (en) Sulfonamide pharmaceutical composition
EP2837390A1 (en) Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
EP3154551B1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN116270715B (zh) Otud5在制备防治心肌缺血再灌注损伤药物中的应用
ES2370790B2 (es) Uso de oxalacetato en el tratamiento de isquemia.
US10653685B2 (en) Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases
CN112334144A (zh) 培养上清液制剂的制造方法
CN118370757A (zh) Fen1抑制剂在制备治疗心肌梗死药物中的应用
US20170106011A1 (en) Methods of treating traumatic brain injury and sequelae
CN102895671B (zh) 一种微小rna在预防和/或治疗心脏疾病中的用途
WO2015084706A1 (en) Intra-articular formulations and methods for treatment of osteoarthritis
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
JP2012522770A (ja) 急性心筋梗塞に対する初期対応におけるリボースの使用
WO2016074203A1 (zh) 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途
HK40097424A (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途
CN120459270A (zh) OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用
CN119367338A (zh) 天然产物苏木查尔酮作为成纤维细胞激活蛋白抑制剂的应用
CN105078993B (zh) 一种吲唑类化合物组合物及其制备方法和应用
WO2023151638A1 (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180525